FTRE Stock Overview
A contract research organization, primarily engages in the provision of biopharmaceutical product and medical device development services worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Fortrea Holdings Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$23.34 |
| 52 Week High | US$41.02 |
| 52 Week Low | US$23.17 |
| Beta | 0 |
| 1 Month Change | -15.28% |
| 3 Month Change | -41.66% |
| 1 Year Change | -27.06% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -22.46% |
Recent News & Updates
Shareholder Returns
| FTRE | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | -7.7% | -1.4% | 1.6% |
| 1Y | -27.1% | 0.8% | 22.3% |
Return vs Industry: FTRE underperformed the US Life Sciences industry which returned 0.8% over the past year.
Return vs Market: FTRE underperformed the US Market which returned 22.3% over the past year.
Price Volatility
| FTRE volatility | |
|---|---|
| FTRE Average Weekly Movement | 7.0% |
| Life Sciences Industry Average Movement | 7.0% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in US Market | 15.5% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: FTRE's share price has been volatile over the past 3 months.
Volatility Over Time: FTRE's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2023 | 16,000 | Tom Pike | www.fortrea.com |
Fortrea Holdings Inc., a contract research organization, primarily engages in the provision of biopharmaceutical product and medical device development services worldwide. The company operates through two segments: Clinical Services and Enabling Services. The Clinical Services segment provides across the clinical pharmacology and clinical development spectrum.
Fortrea Holdings Inc. Fundamentals Summary
| FTRE fundamental statistics | |
|---|---|
| Market cap | US$2.15b |
| Earnings (TTM) | -US$91.20m |
| Revenue (TTM) | US$3.08b |
0.7x
P/S Ratio-22.9x
P/E RatioIs FTRE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| FTRE income statement (TTM) | |
|---|---|
| Revenue | US$3.08b |
| Cost of Revenue | US$2.60b |
| Gross Profit | US$475.90m |
| Other Expenses | US$567.10m |
| Earnings | -US$91.20m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.02 |
| Gross Margin | 15.47% |
| Net Profit Margin | -2.96% |
| Debt/Equity Ratio | 101.5% |
How did FTRE perform over the long term?
See historical performance and comparison